GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avax Technologies Inc (OTCPK:AVXT) » Definitions » Debt-to-Equity

Avax Technologies (Avax Technologies) Debt-to-Equity : 0.00 (As of Sep. 2008)


View and export this data going back to . Start your Free Trial

What is Avax Technologies Debt-to-Equity?

Avax Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2008 was $0.00 Mil. Avax Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2008 was $0.00 Mil. Avax Technologies's Total Stockholders Equity for the quarter that ended in Sep. 2008 was $-2.09 Mil. Avax Technologies's debt to equity for the quarter that ended in Sep. 2008 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Avax Technologies's Debt-to-Equity or its related term are showing as below:

AVXT's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Avax Technologies Debt-to-Equity Historical Data

The historical data trend for Avax Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avax Technologies Debt-to-Equity Chart

Avax Technologies Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 0.31 0.06 1.05 -

Avax Technologies Quarterly Data
Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avax Technologies's Debt-to-Equity

For the Biotechnology subindustry, Avax Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avax Technologies's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avax Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Avax Technologies's Debt-to-Equity falls into.



Avax Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Avax Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2007 is calculated as

Avax Technologies's Debt to Equity Ratio for the quarter that ended in Sep. 2008 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avax Technologies  (OTCPK:AVXT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Avax Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Avax Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Avax Technologies (Avax Technologies) Business Description

Traded in Other Exchanges
N/A
Address
9200 Indian Creek Parkway, Suite 200, Overland Park, KS, USA, 66210
Avax Technologies Inc is a development stage biotechnology company. The company is engaged in the development and commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. It also involved in the development and commercial readiness in the immuno-oncology arena.
Executives
Carl Spana director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Prendergast John K A director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017

Avax Technologies (Avax Technologies) Headlines

No Headlines